SCM
MLTX icon

Silverarc Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Silverarc Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-65,000
Closed -$466K – 86
2025
Q3 		$466K Buy
+65,000
New +$3.39M 0.06% 74

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Silverarc Capital Management's MLTX Position: Q4 2025 in Review

Silverarc Capital Management sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2025, closing a stake of 30,000 shares — an estimated $215K sold.

Silverarc Capital Management first reported a position in MLTX in Q4 2020 and held it in 10 quarters. The position peaked at $10.2M in Q2 2023. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

  • Silverarc Capital Management reported no remaining MoonLake Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Silverarc Capital Management sold 30,000 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $215K.
  • Silverarc Capital Management first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 10 quarters.
  • Silverarc Capital Management's MoonLake Immunotherapeutics position peaked at $10.2M in Q2 2023.
  • 130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on Silverarc Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.